Login
$OKUR
$2.75 +$0.12 (4.56%) Live

$OKUR 8-K SEC Filings

Filed On Filing
04 Nov 2026 8-K: Results of Operations and Financial Condition

-- Announces PANORAMA, an OnKure-sponsored, large-scale, multiregional registry designed to characterize the natural disease course and treatment patterns of people living with vascular anomalies

13 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation

On August 7, 2026 (the “Effective Date”), the Board of Directors (the “Board”) of OnKure Therapeutics, Inc. (the “Company”) approved an option repricing. The repricing generally applied to all outstanding and unexercised stock options to...

04 Aug 2026 8-K: Results of Operations and Financial Condition

-- Executing IND-enabling activities for next-generation PI3Ka pan-mutant selective candidates OKI-345 in breast cancer and OKI-355 in vascular anomalies, with IND submissions planned for 1H 2027

04 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

to attract and retain the best available personnel for positions of substantial responsibility,

05 May 2026 8-K: Results of Operations and Financial Condition

-- Announced nomination of OKI-355, a next-generation PI3Ka pan-mutant selective inhibitor candidate, in vascular anomalies

30 Mar 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”), is made and entered into as of March 27, 2026, by and among OnKure Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Exhibit A attached ...

12 Mar 2026 8-K: Results of Operations and Financial Condition

-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026; continued enrollment in breast cancer triplet combinations

06 Nov 2025 8-K: Entry into a Material Definitive Agreement

OnKure Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:

06 Nov 2025 8-K: Results of Operations and Financial Condition

-- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients with metastatic breast cancer

12 Aug 2025 8-K: Results of Operations and Financial Condition

-- PIKture-01, a phase 1 clinical trial assessing OKI-219 in patients with advanced solid tumors, including breast cancer, is on track for single agent and fulvestrant combination data in Q4 2025

26 Jun 2025 8-K: Regulation FD Disclosure

Legends Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties of OnKure Therapeutics, Inc. (“OnKure” or the “Company”). All statements other than statements of h...

28 May 2025 8-K: Submission of Matters to a Vote of Security Holders

On May 27, 2025, OnKure Therapeutics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on the two proposals set forth below. A more detailed...

06 May 2025 8-K: Results of Operations and Financial Condition

-- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data

10 Mar 2025 8-K: Results of Operations and Financial Condition

-- PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024

10 Dec 2024 8-K: Regulation FD Disclosure; Other Events

OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219

07 Nov 2024 8-K: Changes in Registrant's Certifying Accountant; Other Events

Results of Review of Condensed Interim Financial Information

08 Oct 2024 8-K: Completion of Acquisition or Disposition of Assets; Unregistered Sales of Equity Securities +7 more

We have audited the accompanying balance sheets of OnKure, Inc. (the Company) as of December 31, 2023 and 2022, the related statements of operations and comprehensive loss, changes in convertible preferred stock and stockholders’ deficit...

02 Oct 2024 8-K: Submission of Matters to a Vote of Security Holders

At a special meeting of the stockholders of Reneo Pharmaceuticals, Inc. (“Reneo” or the “Company”) held on September 26, 2024 (the “Reneo Special Meeting”), the Company’s stockholders voted on the proposals set forth below relating to th...

20 Sep 2024 8-K: Other Events

As previously disclosed, on May 10, 2024, Reneo Pharmaceuticals, Inc., a Delaware corporation (“Reneo” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Radiate Merger Sub ...

13 Sep 2024 8-K: Departure/Election of Directors or Officers; Compensation

In connection with the contemplated merger transaction between Reneo Pharmaceuticals, Inc. (the “Company”) and OnKure, Inc. and the cessation of the Company’s historical drug development efforts, the Company terminated the employment of ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support